MOLÉCULAS EN INVESTIGACIÓN

 

MOLÉCULAS EN INVESTIGACIÓN

 

Nuestro compromiso en oncología es impulsar la innovación científica. Esto se refleja en nuestra amplia cartera de nuevas terapias dirigidas y estrategias inmuno-oncológicas, así como en el estudio de combinaciones innovadoras de estas.

 

CANCER CELL-DIRECTED

CANCER CELL-DIRECTED

brigimadlin
(MDM2-p53 antagonist) (III)*

zongertinib
(HER2 TKI) (III)*

KRAS multi-inhibitor (I)*

 

IMMUNO-ONCOLOGY: T-CELL ENGAGERS

IMMUNO-ONCOLOGY: T-CELL ENGAGERS

DLL3/CD3
T-cell engager (II)*

B7-H6/CD3
T-cell engager (I)*

 

IMMUNO-ONCOLOGY: CANCER VACCINES AND ONCOLYTIC VIRUSES

IMMUNO-ONCOLOGY: CANCER VACCINES AND ONCOLYTIC VIRUSES

KISIMATM cancer vaccine
(ATP150/ATP152) and VSV-GP154 (I)*

VSV-GP oncolytic virus (I)*

 

IMMUNO-ONCOLOGY: IMMUNO-MODULATORS

IMMUNO-ONCOLOGY: IMMUNO-MODULATORS

ezabenlimab
(PD-1 inhibitor) (II)*

CD137/FAP bispecific
agonist antibody (I)*

SIRPα antagonist (I)*

2nd generation
STING agonist (I)*

Fase desarrollo

*Al hacer clic en este enlace está accediendo a una página web extranjera que puede contener publicidad sobre medicamentos o indicaciones no autorizadas en España.

Pipeline compounds shown here are under clinical investigation and have not been approved. Their safety and efficacy have not been established.

Current as of May 2024.

 

Referencias

 

(I), Phase 1 clinical trial; (II), Phase 2 clinical trial; (III), Phase 3 clinical trial; CD, cluster of differentiation; DLL3, delta-like ligand 3; FAP, fibroblast activation protein; GP, glycoprotein; HER2, human epidermal growth factor receptor 2; KRAS, Kirsten RAt Sarcoma viral oncogene; MDM2, murine double minute 2; p53, tumor protein 53; PD-1, programmed cell death protein-1; SIRP, signal regulatory protein alpha; STING, stimulator of interferon genes; TKI, tyrosine kinase inhibitor; VSV, vesicular stomatitis virus.

 

SC-ES-16137-072024